Nemluvio was well tolerated and showed sustained improvements in moderate to severe prurigo nodularis during a 2-year treatment period, according to long-term extension data presented at the ...

Original results from the phase 3 OLYMPIA 1 (NCT04501679) and 2 (NCT04501666) trials demonstrated the safety and efficacy of nemolizumab administered subcutaneously every 4 weeks in 560 patients ...

Exciting times are ahead in the next few years for the prurigo nodularis treatment market as it is projected to grow to $2.11 billion in 2029, marking a compound annual growth rate CAGR of 5.1%.

ZUG, Switzerland, June 18, 2025--Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe ...

Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5 (4):e42. doi: 10.1097/itx.0000000000000042 ...

Prurigo nodularis is an inflammatory condition related to the skin’s nerve and immune cells, so there isn’t much you can do ...

This randomized, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the safety and efficacy of povorcitinib (INCB54707) in adult patients with prurigo nodularis (PN ...

The firm’s CHF 133 price target implies nearly 9% upside from current levels. Barclays also initiated Zealand Pharma with an Overweight rating and DKK 560 price target, pointing to a compelling ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US ...

Galderma’s Nemluvio (nemolizumab) has demonstrated sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, according to results from a long-term extension ...

Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data ...